Zentalis Pharmaceuticals has raised approximately USD 80.5 million in an equity offering as it heads toward a potentially registration-enabling readout for azenosertib, its oral WEE1 inhibitor in Cyclin E1-positive platinum-resistant ovarian cancer. The San Diego biotech priced 23 million shares at USD 3.50 each, with proceeds earmarked primarily for the late-stage program and pre-commercial activities.
The financing comes ahead of topline data from the Phase II DENALI Part 2 study, expected by year-end 2026, which could provide the basis for an accelerated approval filing subject to the results and FDA feedback. A randomized Phase III confirmatory study, ASPENOVA, is already underway. Notably, Zentalis narrowed its pipeline to focus solely on azenosertib in a January 2025 restructuring that reduced headcount by approximately 40%.
The offering was priced on August 13, 2026, and is expected to close on August 17. Zentalis also granted underwriters a 30-day option to purchase up to an additional 3.45 million shares at the offering price.
Azenosertib is being evaluated under a dual-track regulatory strategy. The Phase II DENALI study (NCT05128825) is evaluating the WEE1 inhibitor in Cyclin E1-positive PROC at the pivotal dose of 400 mg once daily on a five-days-on, two-days-off schedule. Zentalis selected the dose following an interim analysis in April, with topline Part 2 data expected by year-end. Positive results could potentially support an accelerated approval application, subject to FDA feedback. In DENALI Part 1b, azenosertib produced a 34.9% ORR among 43 response-evaluable Cyclin E1-positive patients.